Mitchell E Horwitz1. 1. Duke University Medical Center, Durham, NC, USA. Mitchell.horwitz@duke.edu
Abstract
PURPOSE OF REVIEW: Use of a reduced intensity conditioning (RIC) regimen has now become standard practice among older or more infirmed stem cell transplantation candidates. Encouraging outcome in this population has led to the question of whether RIC should replace standard myeloablative conditioning (MAC) regimens. This review will summarize the available outcomes data comparing RIC and MAC approaches to stem cell transplantation in adult patients with acute myeloid leukemia, myelodysplastic syndrome (MDS) and acute lymphoid leukemia. RECENT FINDINGS: There are currently no completed prospective randomized controlled studies comparing outcomes of RIC to MAC. The best insight into differences in outcome comes from large registry-based retrospective studies. These studies demonstrate that the use of RIC is associated with a reduction in transplant-related mortality but an increased risk of disease relapse. As a result, for patients undergoing stem cell transplantation in remission, disease free and overall survival are similar. SUMMARY: The current retrospective data provide justification for the use of RIC regimens in all adult stem cell transplant candidates with acute leukemia in remission and MDS. More definitive conclusions regarding differences between the MAC and RIC approach to stem cell transplantation await results of ongoing prospective randomized trials.
PURPOSE OF REVIEW: Use of a reduced intensity conditioning (RIC) regimen has now become standard practice among older or more infirmed stem cell transplantation candidates. Encouraging outcome in this population has led to the question of whether RIC should replace standard myeloablative conditioning (MAC) regimens. This review will summarize the available outcomes data comparing RIC and MAC approaches to stem cell transplantation in adult patients with acute myeloid leukemia, myelodysplastic syndrome (MDS) and acute lymphoid leukemia. RECENT FINDINGS: There are currently no completed prospective randomized controlled studies comparing outcomes of RIC to MAC. The best insight into differences in outcome comes from large registry-based retrospective studies. These studies demonstrate that the use of RIC is associated with a reduction in transplant-related mortality but an increased risk of disease relapse. As a result, for patients undergoing stem cell transplantation in remission, disease free and overall survival are similar. SUMMARY: The current retrospective data provide justification for the use of RIC regimens in all adult stem cell transplant candidates with acute leukemia in remission and MDS. More definitive conclusions regarding differences between the MAC and RIC approach to stem cell transplantation await results of ongoing prospective randomized trials.
Authors: Christopher G Kanakry; Paul V O'Donnell; Terry Furlong; Marcos J de Lima; Wei Wei; Marta Medeot; Marco Mielcarek; Richard E Champlin; Richard J Jones; Peter F Thall; Borje S Andersson; Leo Luznik Journal: J Clin Oncol Date: 2014-09-29 Impact factor: 44.544
Authors: D L Kendler; J J Body; M L Brandi; R Broady; J Cannata-Andia; M J Cannata-Ortiz; A El Maghraoui; G Guglielmi; P Hadji; D D Pierroz; T J de Villiers; R Rizzoli; P R Ebeling Journal: Osteoporos Int Date: 2018-09-03 Impact factor: 4.507
Authors: Junya Kanda; Gwynn D Long; Cristina Gasparetto; Mitchell E Horwitz; Keith M Sullivan; John P Chute; Ashley Morris; Michael Shafique; Zhiguo Li; Nelson J Chao; David A Rizzieri Journal: Biol Blood Marrow Transplant Date: 2013-11-20 Impact factor: 5.742
Authors: Jan J Cornelissen; Alois Gratwohl; Richard F Schlenk; Jorge Sierra; Martin Bornhäuser; Gunnar Juliusson; Zdenek Råcil; Jacob M Rowe; Nigel Russell; Mohamad Mohty; Bob Löwenberg; Gerard Socié; Dietger Niederwieser; Gert J Ossenkoppele Journal: Nat Rev Clin Oncol Date: 2012-09-04 Impact factor: 66.675
Authors: S Fadilah Abdul Wahid; Nor-Azimah Ismail; Mohd-Razif Mohd-Idris; Fariza Wan Jamaluddin; NorRafeah Tumian; Ernie Yap Sze-Wei; Norasiah Muhammad; Ming Lai Nai Journal: Stem Cells Dev Date: 2014-09-17 Impact factor: 3.272
Authors: Rachel B Salit; Daniel H Fowler; Robert M Dean; Steven Z Pavletic; Frances T Hakim; Seth M Steinberg; Nancy T Hardy; Claude Sportes; Ronald E Gress; Michael R Bishop Journal: Biol Blood Marrow Transplant Date: 2013-08-13 Impact factor: 5.742